Related Experiment Video
Updated: May 12, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Laboratory-Scale Production of Recombinant IgG Antibodies
Takahiro Anzai1,2, Masahiro Yasunaga3
1Department of Chemistry and Materials Science, National Institute of Technology (KOSEN), Gunma College, Maebashi, Gunma, 370-8531, Japan. tak-anzai@umin.ac.jp.
None:
The development of hybridoma technology by Köhler and Milstein revolutionized the field of antibody research, paving the way for the creation of monoclonal antibodies. Due to their ability to specifically bind target molecules via antigen-antibody reactions, antibodies have become a major focus in therapeutic development. However, antibodies obtained from immunized animals such as mice may cause immunogenicity or side effects when administered to humans. While humanized mice offer a solution, their high-cost limits widespread adoption. Advances in genetic engineering technology have made it possible to create chimeric antibodies or humanized antibodies and have greatly reduced immunogenicity. In this chapter, we explain in detail a laboratory-scale protocol to produce recombinant IgG antibodies at the milligram scale, which is essential for in vivo research, using transient expression in CHO cells.
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Production of Pharmaceuticals
Upstream Processing

